Abstract: Novel compounds having strong TXA2 receptor antagonist activities and PGI2 receptor agonist activities, which are effective for therapy and prevention of diseases related to TXA2, are disclosed. The compound of the present invention is represented by the following formula (I). (wherein the meanings of the symbols in the formula are as described in the specification).

Abstract: Novel compounds having strong TXA.sub.2 receptor antagonist activities and PGI.sub.2 receptor agonist activities, which are effective for therapy and prevention of diseases related to TXA.sub.2, are disclosed. The compound of the present invention is represented by the following formula (I). ##STR1## (wherein the meanings of the symbols in the formula are as described in the specification).

Abstract: An agent which is chemically stable, which prominently inhibits metastasis of malignant tumor and which is safe is disclosed. The antimetastasis agent of malignant tumors according to the present invention comprises as an effective ingredient beraprost or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses sulfonamide derivative represented by the following general formula: ##STR1## [wherein, R.sub.1 is(i) --COOR.sub.2 (where, R.sub.2 is (1) hydrogen, (2) a pharmacologically acceptable cation, or (3) an alkyl having 1 to 14 carbon atoms) or,(ii) --C(.dbd.O)--R.sub.3 (wherein, R.sub.3 represents an alkyl having 1 to 4 carbon atoms); A is(i) --(CH.sub.2)n-- (wherein, n represents an integer of 0 to 3),(ii) --CH.dbd.CH--, or the group:(iii) --O--C(R.sub.4) (R.sub.5)-- (wherein, R.sub.4 and R.sub.5 represent (1) hydrogen or (2) an alkyl having 1 to 4 carbon atoms, and R.sub.4 and R.sub.5 may be identical or different); and,w is NH or --O--], as well as a thromboxane A2 receptor antagonistic drug having said derivative for its active ingredient.Since the compound of the present invention has excellent thromboxane A2 receptor antagonistic action, it can be used as a thromboxane A2 receptor antagonist of high activity and long duration.

Abstract: The present invention provides a process for preparing 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivative using 3a,8b-cis-dihydro-3H-5,7-dibromocyclopenta[b]benzofuran as a starting material, as well as compounds which are intermediates.

Abstract: Disclosed are 2,5,6,7-tetranor-4,8-inter-m-phemylene PGI.sub.2 derivatives such as 16-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, 17-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, 15-phenyl-2,5,6,7,16,17,18,19,20-nonanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, 16,16-dimethyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-16-phenoxy-2,5,6,7,17,18,19,20-octanor-4,8-inter-m-phenylene PGI.sub.2, 16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor-4,8-inter-m-phenylene PGI.sub.2 and methyl ester thereof, and 3-decarboxy-3-hydroxymethyl-16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor -4,8-inter-m-phenylene PGI.sub.2, which are useful as pharmaceuticals.These compounds are useful as an antiulcer drug, antihypertensive drug, antithrombus drug or the like.

Abstract: The present invention provides a process for preparing 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivative [VII] using 3a,8b-cis-dihydro-3H-5,7-dibromocyclopenta[b]benzofuran (1) as a starting material, as well as compounds of the formulae (8) and (11) which are intermediates for the preparation of the compound of the formula (1).

Abstract: Pharmaceutically useful compounds are 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 derivatives which are excellently stable and potent in vivo.

Abstract: In a mixing liquid ratio detector device, a LED and a photo diode are provided in a manner to sandwich an optically permeable column. The light emitting area of the LED and the light receiving area of the photo diode are each arranged in the neighborhood of the column in generally perpendicular relationship with a boundary between a mixing liquid and the column, such that light beams from the LED enter the boundary through one side of the column, the light beams incident on the boundary at an angle more than a critical angle being totally reflected from the boundary, and advancing through an inner portion of the column to come out from the other side of the column, and impinging on the photo diode.

Abstract: A detector device for mixing ratio for gasoline and alcohol include an optically permeable column, one end of which is coated with a light-reflective layer. The circumferential surface of the column is at least partly immersed in mixing liquid of gasoline and alcohol.The light beams enter the column to be incident on said circumferential surface of the column and reflect from the circumferential surface to be incident on said light reflective-layer to reflect therefrom. The reflected light beams impinge on a photo diode which outputs in accordance with the intensity of the light beams impinged.The diametrical and lengthwise dimension of the column being determined such as to provide incidence angles of the reflected light beams changing from a minimum angle corresponding to the critical angle when the mixing liquid ratio is at the lower limit of the predetermined range to a maximum angle corresponding to the critical angle when the mixing liquid ratio is at the upper limit of the predetermined range.

Abstract: Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent physiological activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined herein.

Abstract: Pharmaceutically useful compounds are 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives such as5,6,7-trinor-4,8-inter-m-phenylene-2-nor-16,16-dimethyl PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(S)-methyl PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(R)-methyl PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2-nor-16,16-dimethyl-.omega.-homo PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(S)-methyl-.omega.-homo PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2-nor-17(R)-methyl-.omega.-homo PGI.sub.2,5,6, 7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16,16-dimethyl-16-p ropoxy PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2,18,19,20-tetranor-16,16-dimethyl-17-et ho xy PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2,18,19,20-tetranor-16,16-dimethyl-17-pr op oxy PGI.sub.2,5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16-phenoxy PGI.sub.2 and methyl esters thereof.5,6,7-trinor-4,8-inter-m-phenylene-2,17,18,19,20-pentanor-16,16-dimethyl-16 -phenoxy PGI.sub.

Abstract: Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, X, R.sub.2 and R.sub.3 are as defined herein.

Abstract: Pharmaceutically useful compounds are 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives such as 5,6,7-trinor-4,8-inter-m-phenylene-13,14-didehydro PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-16,16-dimethyl PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-17-.alpha.-methyl-20-homo PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-17,18,19,20-tetranor-16-phenoxy PGI.sub.2, 5,6,7-trinor-4,8-inter-m-phenylene-20-isopropylidene PGI.sub.2, 5,6,7-trinor-4,8-inter-(5-methyl-1,3-phenylene) PGI.sub.2, and 5,6,7-trinor-4,8-inter-m-phenylene-2,3-didehydro-16,17,18,19,20-pentanor-1 5-phenyl PGI.sub.2. They are useful in treatment of ulcers, thrombii and hypertension for example.

Abstract: A compound of the formula ##STR1## wherein R.sup.1 is a pharmaceutically acceptable cation, hydrogen or n-alkyl of 1 to 12 carbon atoms; R.sup.2 is hydrogen, acyl of 2 to 10 carbon atoms or aroyl of 7 to 13 carbon atoms; R.sup.3 is hydrogen, acyl of 2 to 10 carbon atoms or aroyl of 7 to 13 carbon atoms; R.sup.4 is hydrogen, methyl or ethyl; R.sup.5 is n-alkyl of 1 to 5 carbon atoms; n is an integer of 0 to 4; A is --CH.sub.2 --CH.sub.2 -- or trans --CH.dbd.CH--; and X is --CH.sub.2 --CH.sub.2 -- or trans --CH.dbd.CH--. The compounds are useful in anti-ulcer, hypotensive and platelet aggregation inhibiting compositions.

Abstract: Pharmaceutically useful compounds are 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivatives such as 5,6,7-trinor-4,8-inter-m-phenylene-16,17,18,19,20-pentanor-15-phenyl PGI.sub.2.

Abstract: The degradation of prostaglandins E is prevented or minimized by combining prostaglandins E with methylhesperidin.